31 January 2019
Visiongain has launched a new pharma report Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029 : North America, Europe, India, Rest of the World (RoW).
This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017. It analyses the leading companies operating in the generic drug market and discusses forces that shape companies’ strategic directions. There have been a number of consolidation activities, mergers, acquisitions and divestitures occurring amongst the leading players in the generic drugs market over the last few years. This level of corporate activities has led to the creation of a market which is steep in growth opportunities for companies that are able to align their strategies to growth.
The lead analyst of the report commented "Related to the move towards biosimilars and the decreasing distance between originator and generic companies is the rise of the complex generics sector. As generics competition steadily increases in all markets, there are strong incentives for companies with sufficiently advanced technologies to move beyond simple generics into more complex, higher-margin products.
With differentiation likely to increase in importance as the generics market becomes more competitive, novel delivery systems and reformulations (for example, extended-release versions of original products) will also increase in significance for generics companies. Competitive strength in this field will require investment in ongoing R&D, further contributing to the closure of the gap between original and generic manufacturers."
Leading companies featured in the report include Abbott, Aurobindo, EMS, Endo, Fresenius, Kabi, Mylan, Novartis (Sandoz), Pfizer, Sun Pharmaceuticals, Teva.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.